Nilogen and Scailyte are joining forces to increase the success of cancer therapies in clinics and to advance personalized cancer treatment.
Continue readingNilogen and Scailyte Are Joining Forces to Find the “Right” Treatment for Every Patient
Machine learning meets multi-omics for precision medicine
Bringing industry and academia together to discuss the potential impact of single-cell analytics powered by machine learning for precision medicine.
Continue readingUnderstanding Resistant to CAR-T Immunotherapy to Develop Better Next-generation Therapies
Register for Scailyte’s webinar on “Understanding Resistant to CAR-T Immunotherapy to Develop Better Next-generation Therapies”.webinar single-cell endometriosis research
Continue readingVACANCY: Technical Lead / Product Owner for a clinical diagnostic software
Scailyte is a globally recognised spin-off from ETH Zürich and a pioneer in the field of single-cell data analysis.
Continue readingVACANCY: Data Scientist in Biomarker Discovery
Scailyte is a globally recognized spin-off from ETH Zürich and a pioneer in the field of single-cell data analysis.
Continue readingTrue precision medicine through single-cell science – Nature
ScaiVision identifies disease signatures predicting drug efficacy & drug mode of action. Precision medicine through single-cell science.
Continue readingScailyte AG Announces a partnership with Sirona DX
Scailyte AG announces a strategic partnership with Sirona DX for AI-driven end-point specific single-cell analysis.
Continue readingWEBINAR: Supervised learning of disease-associated cell states and dynamics
Watch Scailyte’s webinar on “Supervised learning of disease-associated cell states and dynamics” with Professor Dr Manfred Classen.
Continue readingPODCAST: Discovering diseases with artificial intelligence
PODCAST: Discovering diseases with artificial intelligence. Listen to this episode of Binary Dreams – Cat!apult with COO Dr. Corinne Solier.
Continue readingScailyte Closes Financing Round and Onboards Top Biotech Leaders
Scailyte has successfully finished the first closing of their series A. Two new investors joined the round, and most of the existing shareholders engaged with follow-on investments. The second closing is planned for the first half of 2022 and Scailyte is currently in discussions with a number of additional investors.
Continue reading